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Objectives The aim of this study was to evaluate whether chronic heart failure (HF) therapy guided by concentrations of
amino-terminal pro–B-type natriuretic peptide (NT-proBNP) is superior to standard of care (SOC) management.
Background It is unclear whether standard HF treatment plus a goal of reducing NT-proBNP concentrations improves out-
comes compared with standard management alone.
Methods In a prospective single-center trial, 151 subjects with HF due to left ventricular (LV) systolic dysfunction were
randomized to receive either standard HF care plus a goal to reduce NT-proBNP concentrations 1,000 pg/ml
or SOC management. The primary endpoint was total cardiovascular events between groups compared using
generalized estimating equations. Secondary endpoints included effects of NT-proBNP–guided care on patient
quality of life as well as cardiac structure and function, assessed with echocardiography.
Results Through a mean follow-up period of 10  3 months, a significant reduction in the primary endpoint of total car-
diovascular events was seen in the NT-proBNP arm compared with SOC (58 events vs. 100 events, p  0.009;
logistic odds for events 0.44, p  0.02); Kaplan-Meier curves demonstrated significant differences in time to
first event, favoring NT-proBNP–guided care (p  0.03). No age interaction was found, with elderly patients bene-
fitting similarly from NT-proBNP–guided care as younger subjects. Compared with SOC, NT-proBNP–guided pa-
tients had greater improvements in quality of life, demonstrated greater relative improvements in LV ejection
fraction, and had more significant improvements in both LV end-systolic and -diastolic volume indexes.
Conclusions In patients with HF due to LV systolic dysfunction, NT-proBNP–guided therapy was superior to SOC, with reduced
event rates, improved quality of life, and favorable effects on cardiac remodeling. (Use of NT-proBNP Testing to
Guide Heart Failure Therapy in the Outpatient Setting; NCT00351390) (J Am Coll Cardiol 2011;58:1881–9)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.072The rising incidence and prevalence of chronic heart failure
(HF) constitutes a major health care burden in both
developed and developing countries (1). In addition, HF is
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although evidence-based therapy for HF has improved
prognosis, rates of adverse outcomes in patients with HF
remain high, with considerable impairment in quality of life
See page 1890
(QOL) for those afflicted. Thus, significant opportunities
exist for the improvement in the evaluation and manage-
ment of patients with HF.
The standard of care (SOC) for outpatient pharmacologic
management of subjects with chronic HF due to left
ventricular systolic dysfunction (LVSD) includes the introduc-
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adrenergic blockers and vasodilators
to achieve clinical trial–based tar-
gets, with the addition of aldoste-
rone blockade or cardiac resyn-
chronization therapy reserved for
those with persistent symptoms
(2). In addition, although loop
diuretic agents are supported to
reduce symptoms in chronic HF,
minimization of doses of these
agents is recommended. How-
ever, ascertainment of clinical
stability and volume status in
chronic HF can be challenging in
inexperienced hands (3). Also,
up-titration of beneficial HF
medications in clinical practice is often suboptimal (4), with
chieved doses lower than in prospective trials (4). In this
egard, an objective biochemical marker for HF stability
ould be invaluable to physicians, particularly if it could be
sed as an adjunctive “guide” to standard HF care.
Trends of amino-terminal pro–B-type natriuretic peptide
NT-proBNP) predict prognosis in chronic HF (5), often
eclining after HF therapy with agents such as vasodilators,
eta-adrenergic blockers, and aldosterone antagonists
6–10), while persistently elevated (or rising) levels of
T-proBNP are predictive of poor outcomes (5). However,
t remains unclear whether adjusting medications on the
asis of standard HF care plus the goal to reduce NT-
roBNP values improves patient outcomes. Previous clinical
rials of various designs have examined this question, re-
urning mixed results (11–18). We therefore wished to
larify the potential role of NT-proBNP–guided HF care.
ethods
he rationale and methods of the PROTECT (Use of
T-proBNP Testing to Guide Heart Failure Therapy in
he Outpatient Setting) study were recently published (19).
riefly, PROTECT was a single-center, investigator-
nitiated, randomized controlled trial with a primary hy-
othesis that standard guideline-compliant HF care with an
djunctive goal to lower and sustain NT-proBNP concen-
rations1,000 pg/ml would be superior to SOC treatment
or patients with HF due to LVSD (left ventricular [LV]
jection fraction 40%). Inclusion and exclusion criteria for
he trial are detailed in Online Table 1. The Partners
ealthcare Institutional Review Board approved all study
rocedures.
After providing consent, patients were block-randomized
n the basis of their New York Heart Association functional
lass symptom severity. The study was a prospective, ran-
omized, open-label, blinded endpoint trial, with endpoints
djudicated blinded to treatment allocation or biomarker
Abbreviations
and Acronyms
GEE  generalized
estimating equations
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
LV  left ventricular
LVSD  left ventricular
systolic dysfunction
NT-proBNP  amino-
terminal pro–B-type
natriuretic peptide
QOL  quality of life
SOC  standard of careevel in the office. Patients were free to withdraw from the arial at any time, but outcomes were analyzed per intent to
reat.
tudy procedures. After randomization, a subject was
ssessed at scheduled clinic visits in the Massachusetts
eneral Hospital Heart Center quarterly, to a maximum of
2 months, or until the last subject was randomized and
ompleted a 6-month follow-up visit. For both treatment
rms, a sample of blood for standard laboratory testing and
T-proBNP measurement (Roche Diagnostics, Inc., Indi-
napolis, Indiana) was obtained. The Minnesota Living
ith Heart Failure Questionnaire was administered at each
linic visit, and 2-dimensional echocardiography was per-
ormed at baseline and (when possible) at the completion of
tudy procedures; performance and interpretation of the
chocardiograms were blinded to NT-proBNP results.
atient management. Patients were managed by physi-
ians skilled in HF care, according to consensus guidelines
2), with the goal of a maximally tolerated neurohormonal
ntagonist or beta-adrenergic blocker medication program
nd concomitant efforts to minimize loop diuretic doses
hen possible. For the NT-proBNP arm, those with
T-proBNP concentrations above 1,000 pg/ml (a thresh-
ld associated with increased risk in HF [5,20–22]) were
onsidered for drug therapy intensification and/or careful
eassessment of their medical programs irrespective of clin-
cal status or perception of the presence of an optimal
edical program. In the NT-proBNP arm, neither caregiv-
rs nor patients were blinded to the NT-proBNP results. As
oted in our methods report (19), although clinicians were
eminded of the sequence and goal doses for the therapies
pplied in the PROTECT study, no algorithm for drug
herapy introduction or intensification was used, as it was
elieved that such an approach would confound the concept
f standard HF management, which does not typically rely
n such algorithmic care.
If adjustment of medical therapy was deemed necessary
or either treatment arm, the choice of medication was made
y the clinician, and follow-up visits were made until
ptimal medical therapy was achieved, a clear therapeutic
imit was reached, or the subject required hospitalization.
rimary endpoint. The primary clinical endpoint of the
ROTECT study was total cardiovascular events, a com-
osite of the following: worsening HF (defined as new or
orsening symptoms or signs of HF requiring unplanned
ntensification of decongestive therapy), hospitalization for
F (including treatment with intravenous diuretic agent in
he emergency department setting without hospitalization),
linically significant ventricular arrhythmia, acute coronary
yndromes, cerebral ischemia, and cardiac death; specific
efinitions of endpoints are described elsewhere (19).
ample size. An initial goal enrollment of 300 subjects was
stimated on the basis of effect sizes and outcomes of
revious studies (19). To minimize the type I error rate, only
interim analysis was planned and was performed upon
nrollment of 151 subjects. As reported (19), the interim
nalysis indicated a statistically significant reduction in the
S
c
c
a
(
p
c
0
m
p
p
h
c
e
4
c
m
4
a
N
N
2
t
a
l
b
N
a
4
h
b
5
O
1883JACC Vol. 58, No. 18, 2011 Januzzi et al.
October 25, 2011:1881–9 Natriuretic Peptide–Guided Heart Failure Therapyprimary endpoint of total cardiovascular events, favoring the
NT-proBNP arm. On the basis of the magnitude of
reduction in events related to NT-proBNP allocation and
the results of recent trials, a decision was made to suspend
active enrollment, with planned 6-month follow-up for the
remaining active patients.
Statistical analysis. Differences in characteristics between
subjects in each arm were assessed using chi-square tests for
categorical variables and Student t tests or Wilcoxon rank
sum tests for continuous variables, as appropriate. For the
primary endpoint, comparison of event rates between study
arms was performed using generalized estimating equations
(GEE), a method used to correct for multiple events within
some subjects (23); from the GEE, a logistic beta coefficient
was calculated for the differential effect of adding NT-
proBNP results to clinical management of HF, after adjust-
ing for age, LV ejection fraction, New York Heart Associ-
ation functional class, and estimated glomerular filtration
rate; from this beta coefficient, logistic odds and 95%
confidence intervals were estimated. Hosmer-Lemeshow
testing was applied to assess model fit. Time-to-first-event
analyses were performed using the Kaplan-Meier method,
and groups were compared using the log-rank test.
Associations between treatment strategy and treatment-
related serious adverse events were examined, after adjust-
ment for relevant baseline covariates, such as estimated
glomerular filtration rate, potassium, and blood pressure.
Parametric and nonparametric tests were used to examine
therapy changes between treatment groups; all subjects com-
pleting at least 1 follow up visit were included in the analysis of
therapy changes as a function of treatment allocation. Addi-
tionally, we examined the effects of NT-proBNP–guided HF
care on QOL, as well as echocardiographic parameters. A
2-tailed p value 0.05 was considered to indicate statistical
significance. All analyses were performed using Stata version
9.2 (StataCorp LP, College Station, Texas) or PASW version
17 (SPSS, Inc., Chicago, Illinois).
Results
Patient demographics, study visits, and therapeutic in-
terventions. Figure 1 details the study flow; of 151 ran-
domized patients, there were 6 withdrawals in each arm.
Table 1 details baseline patient characteristics for the trial.
The mean age of the study population was 63.3  13.9
years; 21.9% were 75 years of age.
Over a mean follow-up period of 10  3 months, study
subjects made 908 visits, with a median number of 5.0 visits
(interquartile range: 4.0 to 8.0 visits); those in the NT-
proBNP arm were seen a median of 6.0 times, while those
in the SOC arm were seen a median of 5.0 times (p 0.05).
ubjects age 75 years were seen a median of 7.5 times,
ompared with 5.0 times in those age 75 years (p  0.001).
Tables 2 and 3 depict HF therapies at baseline and at the
ompletion of the study. The majority of patients in both
rms entered the study on guideline-based medical regimens oTable 2). During study procedures, patients in the NT-
roBNP arm had an average of 7 therapy adjustments
ompared with SOC-managed patients, who had 6 (p 
.23 for difference), although dosing changes were typically
ore aggressive in the NT-proBNP arm (Table 3). The
roportion achieving 50% goal doses (2) for their thera-
ies was consistently numerically (but not statistically)
igher in the NT-proBNP arm; this included angiotensin-
onverting enzyme inhibitors or angiotensin receptor block-
rs (56.5% vs. 50.8%), as well as beta-blockers (53.4% vs.
1.9%). Notably, at the completion of the study (Table 2),
ompared with SOC, patients in the NT-proBNP arm were
ore likely to be taking aldosterone blockers (62.7% vs.
4.7%, p  0.001) and less likely to be taking loop diuretic
gents (85.3% vs. 96.1%, p  0.05).
T-proBNP concentrations. At baseline, the median
T-proBNP concentration for the group as a whole was
,118 pg/ml (interquartile range: 1,122 to 3,831 pg/ml);
here was no difference between the NT-proBNP and SOC
rms with respect to NT-proBNP concentrations at base-
ine (2,344 pg/ml vs. 1,946 pg/ml, p  0.40). After the
study procedures, the median NT-proBNP concentration
for the group as a whole fell to 1,321 pg/ml (p  0.02 vs.
aseline); a significant reduction was seen only in the
T-proBNP arm (to 1,125 pg/ml, p  0.01 vs. baseline),
while the SOC arm had no significant decrease (1,844
pg/ml, p  0.61 vs. baseline and p  0.03 vs. NT-proBNP
rm in follow-up). At the end of the study procedures,
4.3% of the NT-proBNP arm and 35.6% of the SOC arm
ad NT-proBNP values below 1,000 pg/ml; similar distri-
utions of subjects were below 2,000 pg/ml (68.6% vs.
7.5%) and 3,000 pg/ml (80.0% vs. 69.9%).
utcomes. Over the follow-up period of the study, a total
Figure 1 Study Flow
Patients were block-randomized on the basis of heart failure symptom severity
into 1 of 2 treatment strategies; withdrawals were balanced between the
2 arms and analyzed per intent to treat. NT-proBNP  amino-terminal pro–B-
type natriuretic peptide.f 158 events were registered. The mean number of events
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m
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to 2), the latter because the majority of subjects (60.9%) had
no events registered during the study. Of those with events,
72% had 3 or fewer events.
Lower achieved NT-proBNP concentrations were corre-
lated with lower event rates: those below 1,000 pg/ml had
the lowest frequency of events (0.45 events) compared with
those between 1,000 and 2,000 pg/ml (1.1 events), between
2,000 and 3,000 pg/ml (1.25 events), and above 3,000 pg/ml
Baseline Characteristics of the Study Cohortas a Function of Randomiza ionTable 1 B seline Char ct ris ics of t e Study Cohortas a Function of Randomization
Characteristic
NT-proBNP
(n  75)
SOC
(n  76) p Value
Age (yrs) 63.0 14.5 63.5 13.5 0.41
NYHA functional class II or III 65 (85.5%) 64 (84.2%) 0.46
LV ejection fraction 28.0 8.7% 25.9 8.3% 0.52
Men 67 (88.2%) 61 (81.3%) 0.24
Caucasians 65 (85.5%) 66 (88.0%) 0.65
Cause of HF 0.17
Ischemic 40 (53.3%) 45 (60.0%)
Nonischemic 25 (33.3%) 18 (24.0%)
Other 10 (13.3%) 12 (16.0%)
Medical history
Hypertension 40 (52.6%) 39 (52.0%) 0.94
Coronary artery disease 42 (55.3%) 50 (66.7%) 0.09
Myocardial infarction 28 (36.8%) 30 (40.0%) 0.69
Atrial fibrillation 31 (40.8%) 30 (40.0%) 0.92
Ventricular tachycardia 23 (30.3%) 21 (28.0%) 0.76
Obstructive airways disease 15 (19.7%) 16 (21.3%) 0.81
Diabetes mellitus 30 (39.5%) 32 (42.7%) 0.19
Implanted devices
Cardioverter-defibrillator 52 (69.3%) 50 (65.8%) 0.32
Biventricular pacemaker 30 (40.0%) 30 (39.4%) 0.68
Tobacco use 0.94
Active smokers 5 (6.6%) 6 (8.0%)
Never smokers 47 (61.8%) 45 (60.0%)
Ex-smokers 24 (31.6%) 24 (32.0%)
Physical examination
Body mass index (kg/m2) 28.8 6.4 28.5 6.1 0.63
Heart rate (beats/min) 73 13 73 12 0.48
Systolic blood pressure (mm Hg) 108 15 112 16 0.07
Diastolic blood pressure (mm Hg) 64 9 67 9 0.05
Jugular venous distension 24 (31.6%) 30 (40.0%) 0.28
Pulmonary rales 8 (10.5%) 11 (14.7%) 0.44
S4 gallop 6 (7.9%) 9 (12.0%) 0.40
S3 gallop 20 (26.3%) 23 (30.7%) 0.55
Murmur 51 (67.1%) 48 (64.0%) 0.69
Lower extremity edema 26 (34.2%) 21 (28.0%) 0.41
QRS duration (ms) 140 35 137 37 0.70
Laboratory results
Sodium (mmol/l) 138 3.5 138.6 2.6 0.07
Potassium (mg/dl) 4.3 0.4 4.2 0.4 0.71
Blood urea nitrogen (mg/dl) 31.5 16.8 29.6 14.4 0.78
Creatinine (mg/dl) 1.46 0.5 1.49 0.43 0.39
Values are mean  SD or n (%).
HF  heart failure; LV  left ventricular; NT-proBNP  amino-terminal pro–B-type natriuretic
peptide; NYHA  New York Heart Association; SOC  standard of care.(2.0 events) (p  0.001 for trend) (Online Fig. 1). cWith respect to the primary endpoint, those in the
NT-proBNP arm had fewer total cardiovascular events,
compared with the SOC arm (58 events vs. 100 events; p 
.009). The adjusted logistic odds for NT-proBNP–guided
anagement on cardiovascular events were 0.44 (95% con-
dence interval: 0.22 to 0.84; p 0.02). Sensitivity analyses
with removal of events related to acute coronary syndromes
or cerebral ischemia had no effect on the benefits of
NT-proBNP–guided care.
Considered as a function of treatment allocation, those in
the NT-proBNP arm had fewer events per patient (0.77
events vs. 1.3 events, p  0.03), and fewer patients in the
NT-proBNP arm had a single event, compared with the
SOC arm (29.3% vs. 48.6%, p  0.04). Discrete outcome
measures are noted in Table 4. No significant effect on
cardiovascular death was noted associated with NT-
proBNP–guided HF care; notably, 3 of the 4 decedents in
the NT-proBNP had withdrawn from the study before their
deaths.
Kaplan-Meier curves depicting time-to-first-event anal-
yses for the primary endpoint demonstrate a significant
event rate reduction for those in the NT-proBNP arm
(log-rank p  0.03) (Fig. 2).
No interaction between NT-proBNP–guided care and
age was found (p  0.11). NT-proBNP–guided HF man-
agement reduced total cardiovascular events in elderly pa-
tients (age75 years) in a comparable manner as the trial as
a whole (0.71 events vs. 1.71 events, p  0.01; adjusted
logistic odds 0.48, p  0.005).
Safety. No significant difference in serious adverse events
between treatment arms was noted (Table 5).
QOL. Those in the NT-proBNP arm had a larger im-
provement in QOL compared with SOC-treated patients,
with a significantly larger median improvement (10.0 vs.
5.0, p  0.05); NT-proBNP–treated patients were also
more likely to demonstrate large (10-point) improvements
in QOL scores (61.2% vs. 38.8%, p  0.03).
Echocardiographic parameters of LV remodeling. A to-
tal of 116 study participants (60 in the NT-proBNP arm
and 56 in the SOC arm) underwent both baseline and
follow-up echocardiographic studies (Fig. 3). During the
study period, absolute LV ejection fraction improved by a
median of 6.0% (relative change 14.0%). Compared with
SOC, those in the NT-proBNP arm demonstrated greater
absolute (8.3% vs. 4.0%, p  0.06) and relative (18.0% vs.
8.0%, p  0.01) improvements in LV ejection fraction.
Those in the NT-proBNP arm demonstrated greater im-
provement in LV end-systolic volume index (from 65.0 to
48.5 ml/m2, median change 15.6%) compared with SOC
patients (from 55.5 to 48.5 ml/m2, median change 6.7%)
(p  0.001). Similarly, NT-proBNP patients also had more
significant improvements in LV end-diastolic volume index
(from 85.0 to 77.5 ml/m2, median change 8.8%) com-
ared with SOC patients (from 77.0 to 75.0 ml/m2, median
hange 2.5%) (p  0.008).
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Despite the establishment of optimal therapeutic strategies
in chronic HF management, clinical outcomes for affected
patients remain poor, with frequently inadequate applica-
tion of HF therapies in the highest-risk patients. Attempts
have been made to close the existing treatment gap in HF
while improving clinicians’ ability to more accurately iden-
tify and treat patients with HF at risk for impending
complications. Elevated values of natriuretic peptides are
powerfully predictive of adverse outcomes in a manner
additive and/or superior to most traditional prognostic
measures in HF (24), while rising values identify a rising
risk for adverse outcome (5). After initial landmark results
from Troughton et al. (11) from New Zealand establishing
the concept of biomarker-guided care, several studies have
examined this approach; some have shown benefits of
guided therapy (11,14,16), whereas in others, the benefit
was less obvious, with either mixed or totally negative results
(13,15,17,18). Thus, as noted by thought leaders in the
field, an answer regarding this approach is still awaited (25).
In the PROTECT study, against a background of excel-
lent HF care, the addition of NT-proBNP guidance signif-
icantly improved the primary endpoint of total cardiovascu-
lar events for patients with LVSD and was well tolerated,
Medication Use as Mean Changes inDosages During the Course of the StudyTable 3 M dication Use as Mean Changes inDosages During the Course of the Study
Medication
NT-proBNP
(n  75)
SOC
(n  76) p Value
ACE inhibitors 25.4% 18.1% 0.15
Angiotensin receptor blockers 5.8% 22.3% 0.01
Beta-blockers 46.0% 34.5% 0.05
Aldosterone antagonists 22.7% 5.8% 0.001
Loop diuretic agents 23.7% 25.6% 0.65
Thiazide diuretic agents* 16.7% 12.5% 0.88
Digoxin* 10.9% 2.0% 0.78
Hydralazine* 27.5% 50.0% 0.20
Nitrates* 59.4% 3.7% 0.08
Medication Use at Baseline and After Completion of Study ProceduTable 2 Medication Use at Baseline and After Completion of S
Baseline
Medication
NT-proBNP
(n  75)
SOC
(n  76)
ACE inhibitors 53 (70.7%) 47 (61.8%)
Angiotensin receptor blocker 8 (10.7%) 15 (19.7%)
Beta-blockers 74 (98.7%) 71 (93.4%)
Aldosterone antagonists 37 (49.3%) 26 (34.2%)
Loop diuretic agents 67 (89.3%) 71 (93.4%)
Thiazide diuretic agents 5 (6.7%) 3 (4.0%)
Digoxin 22 (29.3%) 25 (32.9%)
Hydralazine 4 (5.3%) 4 (5.3%)
Nitrates 8 (10.7%) 16 (21.1%)
ACE  angiotensin-converting enzyme; other abbreviations as in Table 1.*Limited number of observations
Abbreviations as in Tables 1 and 2.with favorable effects on QOL and significant improve-
ments in LV volumes on echocardiography. Our results thus
suggest that in patients with HF due to LVSD, NT-
proBNP monitoring with aggressive care to lower concen-
trations below a threshold value may be a useful tool to assist
in standard HF care.
Understanding differences among published studies in
this area and their occasionally conflicting results is impor-
tant. Explanations may include heterogeneity in design, the
inclusion of difficult-to-treat populations in HF (such as
those with heart failure with preserved ejection fraction
[HFpEF]), as well as heterogeneity of aggressiveness in
attempts to lower natriuretic peptide concentrations com-
pared with control management.
In our study, we focused solely on LVSD, because the
treatment approach to patients so afflicted is very clearly
defined (26). This is in contrast to HFpEF, for which less
clearly defined treatment options exist to clearly reduce
adverse outcomes. Indeed, HFpEF is widely recognized to
be caused by a heterogeneous group of disease states,
without defined, accepted drug therapies as for LVSD (27);
thus, guided drug therapy may be less useful in this type of
patient. Indeed, a prior study of guided therapy including a
mixture of patients with LVSD and HFpEF (15) suggested
that a trend toward more benefit in those with LVSD was
Outcomes in the PROTECT StudyTable 4 Outcomes in the PROTECT Study
Outcome Measure
NT-proBNP
(n  75)
SOC
(n  76) p Value
Total cardiovascular events 58 100 0.009
Discrete outcome measures
Worsening heart failure 27 54 0.001
HF hospitalization 11 27 0.002
Acute coronary syndromes 9 9 0.72
Significant ventricular arrhythmia 7 4 0.41
Cerebral ischemia 0 0 0.98
Cardiovascular death 4 6 0.52
Subjects with at least 1 event 28.3% 48.6% 0.04
A significant reduction in the primary endpoint of total cardiovascular events was driven by
Procedures
Final
p Value
NT-proBNP
(n  75)
SOC
(n  76) p Value
.21 56 (74.7%) 46 (60.5) 0.20
.11 9 (12.0%) 17 (22.4%) 0.05
.19 73 (97.3%) 73 (96.1%) 0.56
.10 47 (62.7%) 34 (44.7%) 0.001
.27 64 (85.3%) 73 (96.1%) 0.05
.48 5 (6.7%) 3 (3.9%) 0.42
.89 23 (30.7%) 23 (30.3%) 0.90
.89 2 (2.7%) 4 (5.3%) 0.12
.07 7 (9.3%) 14 (18.4%) 0.06restudyimprovements in rates of worsening HF and reduced HF hospitalizations.
Abbreviations as in Table 1.
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HFpEF (17), no mention was made. Thus, it remains
speculative.
Another difference compared with prior studies was the
goal NT-proBNP value of 1,000 pg/ml selected in this
study, as well as, and perhaps most important, the assidu-
ousness of the care given to achieve this goal. Our goal
NT-proBNP value of 1,000 pg/ml was selected on the basis
of clinical trials defining an inflection point of risk at this
concentration (5,20–22); indeed, the results of the PROTECT
study validate this goal value, demonstrating a clear gradient of
risk in subjects with NT-proBNP concentrations above
1,000 pg/ml. In trials with higher target values for NT-
Figure 2 Kaplan-Meier Curves Depicting Outcomes
as a Function of Treatment Assignment
As a function of time to first event, a significant reduction in adverse outcome
was noted in those patients treated with a strategy guided by amino-terminal
pro–B-type natriuretic peptide. SOC  standard of care.
Serious Adverse Events During the Study as a FTable 5 Serious Adverse Events During the
Adverse Event
NT-proBNP (n  75)
Total Events % With 1 Ev
Abdominal pain 1 1.3%
Acute renal failure 4 5.3%
Anemia 1 1.3%
Atrial fibrillation 2 2.7%
Cough 2 2.7%
Diarrhea 2 2.7%
Dizziness 5 6.7%
Fever 1 1.3%
Gastrointestinal bleeding 1 1.3%
Hyperkalemia/hypokalemia 3 2.7%
Hypotension 4 5.3%
Respiratory infection 2 2.7%
Syncope 2 2.7%Abbreviations as in Table 1.proBNP (15), rates of adverse outcome were, not surpris-
ingly, high, with negative results overall. In some other
studies, the goal NT-proBNP values were similar to ours,
but rates of achievement of these goal concentrations were
very low (13,18). For example, in the report of Persson et al.
(18), NT-proBNP concentrations were lowered by approx-
imately 10% from baseline (to approximately 2,360 pg/ml),
a reduction less than biological variability for the biomarker;
thus, the benefit of NT-proBNP lowering was not ade-
quately assessed in that study. In another negative study that
included a large number of elderly subjects, goal NT-
proBNP values were rarely met, despite more drug titration
in the NT-proBNP arm (13); thus, above and beyond
simply triggering drug titration, the available data would
suggest that efforts to lower of NT-proBNP values below a
target value are crucial to reduce risk.
In testing the hypothesis that improved outcomes would
follow reduction of NT-proBNP, we carefully managed
patients with the objective of significant NT-proBNP
lowering and achieved this goal in the highest percent of
subjects in any guided therapy trial reported to date. In
doing so, although both arms of the trial received aggressive
care, we titrated therapies such as aldosterone antagonists
and beta-blockers more aggressively in the NT-proBNP–
guided arm; in addition, NT-proBNP patients were less
likely to be taking loop diuretic agents at the completion of
the study. Given associations between loop diuretic agents,
neurohormonal activation, and adverse outcome in HF (28),
he reduction in use of this class of drugs after NT-proBNP
uidance is an important finding. In comparison, studies
nding no difference between guided therapy and standard
anagement often reported no significant difference in drug
itrations between the biomarker arm and control groups
17,18) or mainly up-titrated loop diuretic agents (15).
verall, however, in our study and others, achievement of
goal” doses of drug was a challenge, even when guided by
on of Treatment Allocationas a Function of Treatment Allocation
SOC (n  76)
p Value for Difference
(in % With 1 Event)Total Events % With 1 Event
1 1.3% 0.90
3 3.9% 0.72
0 0% 0.90
5 6.6% 0.42
1 1.3% 0.41
1 1.3% 0.65
4 5.3% 0.70
1 1.3% 0.89
1 1.3% 0.78
1 1.3% 0.32
0 0% 0.08
4 5.3% 0.25
1 1.3% 0.70unctiStudy
ent
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managing these complex patients well.
The elderly population is at highest risk in chronic HF,
more often demonstrating suboptimal responses to therapy
and greater intolerance to medication titration (13) com-
pared with younger patients; thus, it is not a stretch to assert
that any modality to guide HF care is likely to be more
challenged in the elderly, and biomarker-guided care is no
exception (13,17). However, drug therapy titration in el-
derly patients with HF, although more gradual, may often
be comparably successful with that in younger patients (29).
In our study, we found no clear interaction with age
(modeled as a continuous variable), and subjects 75 years
of age seemed to significantly benefit from NT-proBNP–
guided care, albeit in the context of a relatively limited
number of patients in this age range. It remains speculative
why our results contrast those of other trials, but it may be
due to the larger number of visits in the elderly population
of the PROTECT study, allowing for more gradual, but
ultimately successful, up-titration of therapies. The elderly
are also more likely to have HFpEF, with attendant limi-
tations as mentioned previously.
The more significant improvement in LV ejection frac-
tion and end-systolic and -diastolic volume indexes associ-
ated with NT-proBNP–guided HF care is of great interest,
lending mechanistic support to the event rate reductions
associated with the approach. Therapies that lead to im-
proved remodeling in chronic HF not only have a direct
impact on nonfatal HF events but also typically reduce
mortality (30). Recent meta-analyses suggest a potential
mortality reduction from natriuretic peptide–guided care
(31,32); our results suggest that favorable effects on remod-
Figure 3 Echocardiographic Results Among Patients as a Func
Those with heart failure management guided by NT-proBNP had greater improveme
LV  left ventricular; LVEF  left ventricular ejection fraction; other abbreviationseling may in part explain this finding. More in-depthanalyses of extensive echocardiographic results from the
PROTECT study are forthcoming.
Study limitations. Limitations of our study include that it
was relatively small (although robust) and was performed at
a tertiary care teaching hospital. In addition, the PROTECT
study was a single-center trial; although potentially limiting
generalizability, the single-center nature of the study may be
a strength in a way, because it allowed for strong adherence
to study protocol with maintenance of efforts at NT-
proBNP lowering, something particularly feasible in a
single-center design. Our study design and findings should
be replicated in larger, multicenter analyses, which are
planned. Although outcomes favored NT-proBNP guid-
ance, a primary endpoint of total cardiovascular events may
also be a limitation. However, patients with chronic HF are
a clinically recidivistic population, and use of the GEE
approach allows comparison of the impact of HF therapy
guided by NT-proBNP on these high rates of recurrent
events. In this, we found that NT-proBNP guidance not
only reduced overall event rates but also reduced the risk for
a first event, as evidenced in Kaplan-Meier analysis. Also,
the use of the GEE approach minimizes the risk that a few
patients with a large number of events will influence the
outcome analysis. Although the GEE analysis has value in
this context, we concede that the adjustments applied
within the equations used did include potentially relevant
covariates (such as duration of HF diagnosis, achieved drug
doses, and ischemic vs. nonischemic HF etiology, as well as
many other potential choices), the inclusion of which may
have rendered the model unstable. However, the benefits of
guided therapy were significant in Kaplan-Meier analyses,
as well as in our echocardiographic data, which lends
support to the primary endpoint. The benefits of guided
of NT-proBNP Versus SOC Management
entricular function and more favorable reverse remodeling.
igure 2.tion
nt in v
as in Ftherapy in the elderly subjects of the PROTECT study may
22
2
1888 Januzzi et al. JACC Vol. 58, No. 18, 2011
Natriuretic Peptide–Guided Heart Failure Therapy October 25, 2011:1881–9be questioned, given the limited number of patients in this
age range, which reduces our statistical power compared
with larger landmark studies (13,17); although our mean
age is younger than those of many guided therapy trials, it
is very comparable with the mean ages in clinical trials of
drugs applied to treat HF due to LVSD, which allows
examination of the approach of guided therapy in a patient
population that is consistent with the clinical trials of drug
therapy in HF represented in consensus guidelines. In
addition, as noted, it is unclear if negative results regarding
age and natriuretic peptide–guided HF therapy have to do
with a universal futility of HF therapy in the elderly, or
whether a different approach for such patients compared
with younger patients is needed. Another potential limita-
tion is the use of an unblinded trial design; this could lead
to bias, as managing physicians would be aware of treatment
allocation. Nonetheless, this design has been used in similar
“guided therapy” trials (16), patients in the SOC arm
received excellent, aggressive care, all endpoints were adju-
dicated blinded to treatment allocation, and both QOL and
echocardiographic improvement was seen in parallel with
better outcomes in these subjects.
Conclusions
Against a backdrop of standard HF care, the addition of a
strategy to suppress NT-proBNP values led to significant
reductions in adverse outcomes in a population of patients
with chronic HF. If confirmed, the addition of natriuretic
peptide–guided therapy to standard care may represent a
new paradigm for HF practice.
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